Cargando…

Dog owner flea/tick medication purchases in the USA

BACKGROUND: Veterinary clinic transaction records from the USA were examined to determine dog owner purchase patterns for three prescription ectoparasiticides. In-clinic purchases of formulations of fluralaner (with 12-week duration per dose) were compared with dog owner purchases of afoxolaner and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lavan, Robert, Armstrong, Rob, Tunceli, Kaan, Normile, Dorothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218982/
https://www.ncbi.nlm.nih.gov/pubmed/30400923
http://dx.doi.org/10.1186/s13071-018-3142-8
_version_ 1783368557804912640
author Lavan, Robert
Armstrong, Rob
Tunceli, Kaan
Normile, Dorothy
author_facet Lavan, Robert
Armstrong, Rob
Tunceli, Kaan
Normile, Dorothy
author_sort Lavan, Robert
collection PubMed
description BACKGROUND: Veterinary clinic transaction records from the USA were examined to determine dog owner purchase patterns for three prescription ectoparasiticides. In-clinic purchases of formulations of fluralaner (with 12-week duration per dose) were compared with dog owner purchases of afoxolaner and spinosad (both with 4 week duration per dose) in a population of 231,565 dogs over a 12 month period. Prior studies in human and animal medicine have suggested that patients more closely adhere to prescriber dosing recommendations when they receive a longer-duration medication. RESULTS: Veterinary clinic transaction records were examined for the period June 2014 through March 2017 using records from approximately 650 veterinary clinics. Ectoparasiticide purchase patterns were compared for two products (afoxalaner and spinosad) with monthly dosing and one product (fluralaner) with an extended (12 week) dosing interval. The average dog owner who obtained fluralaner purchased significantly more months of flea/tick protection (5.7 months) over the 12-month study period than the average dog owner that selected either afoxolaner (4.6 months) or spinosad (3.3 months). The proportion of dog owners who obtained only one dose of ectoparasiticide per 12-month period was 42% for fluralaner, 30% for afoxolaner and 37% for spinosad. The proportion of dog owners who obtained 2 doses or less per 12-month period was 67% for fluralaner, 52% for afoxoalaner and 67% for spinosad. Owners that obtained fluralaner were significantly more likely to obtain 7.0–12.0 months of flea and tick protection and significantly less likely to purchase 1.0–6.9 months compared with dog owners who purchased afoxolaner or spinosad. CONCLUSIONS: Dog owners who obtained a flea and tick medication with a longer duration of action acquired significantly more months of protection in a year than dog owners who obtained shorter duration (1 month) products. Dog owners were better able to adhere to veterinary recommendations on ectoparasites control with a longer-acting flea/tick medication.
format Online
Article
Text
id pubmed-6218982
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62189822018-11-08 Dog owner flea/tick medication purchases in the USA Lavan, Robert Armstrong, Rob Tunceli, Kaan Normile, Dorothy Parasit Vectors Short Report BACKGROUND: Veterinary clinic transaction records from the USA were examined to determine dog owner purchase patterns for three prescription ectoparasiticides. In-clinic purchases of formulations of fluralaner (with 12-week duration per dose) were compared with dog owner purchases of afoxolaner and spinosad (both with 4 week duration per dose) in a population of 231,565 dogs over a 12 month period. Prior studies in human and animal medicine have suggested that patients more closely adhere to prescriber dosing recommendations when they receive a longer-duration medication. RESULTS: Veterinary clinic transaction records were examined for the period June 2014 through March 2017 using records from approximately 650 veterinary clinics. Ectoparasiticide purchase patterns were compared for two products (afoxalaner and spinosad) with monthly dosing and one product (fluralaner) with an extended (12 week) dosing interval. The average dog owner who obtained fluralaner purchased significantly more months of flea/tick protection (5.7 months) over the 12-month study period than the average dog owner that selected either afoxolaner (4.6 months) or spinosad (3.3 months). The proportion of dog owners who obtained only one dose of ectoparasiticide per 12-month period was 42% for fluralaner, 30% for afoxolaner and 37% for spinosad. The proportion of dog owners who obtained 2 doses or less per 12-month period was 67% for fluralaner, 52% for afoxoalaner and 67% for spinosad. Owners that obtained fluralaner were significantly more likely to obtain 7.0–12.0 months of flea and tick protection and significantly less likely to purchase 1.0–6.9 months compared with dog owners who purchased afoxolaner or spinosad. CONCLUSIONS: Dog owners who obtained a flea and tick medication with a longer duration of action acquired significantly more months of protection in a year than dog owners who obtained shorter duration (1 month) products. Dog owners were better able to adhere to veterinary recommendations on ectoparasites control with a longer-acting flea/tick medication. BioMed Central 2018-11-06 /pmc/articles/PMC6218982/ /pubmed/30400923 http://dx.doi.org/10.1186/s13071-018-3142-8 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Short Report
Lavan, Robert
Armstrong, Rob
Tunceli, Kaan
Normile, Dorothy
Dog owner flea/tick medication purchases in the USA
title Dog owner flea/tick medication purchases in the USA
title_full Dog owner flea/tick medication purchases in the USA
title_fullStr Dog owner flea/tick medication purchases in the USA
title_full_unstemmed Dog owner flea/tick medication purchases in the USA
title_short Dog owner flea/tick medication purchases in the USA
title_sort dog owner flea/tick medication purchases in the usa
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218982/
https://www.ncbi.nlm.nih.gov/pubmed/30400923
http://dx.doi.org/10.1186/s13071-018-3142-8
work_keys_str_mv AT lavanrobert dogownerfleatickmedicationpurchasesintheusa
AT armstrongrob dogownerfleatickmedicationpurchasesintheusa
AT tuncelikaan dogownerfleatickmedicationpurchasesintheusa
AT normiledorothy dogownerfleatickmedicationpurchasesintheusa